← Leaderboards
Stephen Naylor
Reneurogen, Llc
$4,526,304
Attributed
$4,526,304
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,526,304 · 4
By mechanism
R44$3,966,024 · 2
R43$560,280 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Funding”
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Lynn Briscoe · Leidos Biomedical Research, Inc.$295,272,057
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$251,636,500
Research focus
FundingAmidesSmall Business Innovation Research GrantPharmaceutical PreparationsPharmacodynamicsNovel TherapeuticsToxicologyDrug KineticsBrainProgramsPreventFutureInflammationProductionAdultPharmacologyPreclinical SafetyOxidantsDesignOrganPeroxidasesLungLifePre-Investigational New Drug Meeting
Grant awards (6)
KYC, an inhibitor of sickle cell disease's vicious cycle in vaso-occlusive crisis and pain$1,045,688
R44 · FY2025 · HL · contact PI
Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia$50,000
R44 · FY2025 · HL · contact PI
Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia$1,861,772
R44 · FY2024 · HL · contact PI
Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia$1,008,564
R44 · FY2023 · HL · contact PI
A Novel Myeloperoxidase Inhibitor for Treating Multiple Sclerosis$285,790
R43 · FY2018 · NS · contact PI
KYC Reduces Vasculopathy in Sickle Cell Disease$274,490
R43 · FY2018 · HL · contact PI